The Food and Drug Administration took another step toward granting emergency use authorization to a third COVID-19 vaccine Wednesday, announcing that a single dose of Johnson & Johnson's vaccine showed 86% efficacy against severe cases of disease in a USA trial.
The AstraZeneca and CoviShield COVID-19 vaccines are like the same recipe being prepared in two different kitchens. It would be the third vaccine available in the U.S. to help stop the spread of the illness and the first to require only one dose to be effective. But public health officials warned that those gains may be stalling as more variants take root in the U.S.
Most participants who developed adverse reactions to the vaccine were people between the ages of 18 and 59.
According to the FDA, the latest data submitted by Pfizer attested to a more lenient handling of the undiluted vaccine vials for up to two weeks in conventional freezers.
That potentially puts vector vaccines at a disadvantage to mRNA shots from Pfizer and Moderna, or vaccines using deactivated coronaviruses, like Sinovac's, or the coronavirus' surface spike proteins, an approach pursued by Novavax.
"While there has been an overall shift towards greater enthusiasm for getting a COVID-19 vaccination, the demographic groups that are the most enthusiastic, most cautious, and most resistant remain similar to those reported in January", the researchers wrote in the report.After adding in moderate cases, the total effectiveness dropped to about 66 percent.
The poll found serious side effects to be people's biggest concern about receiving the vaccine, with over half of unvaccinated individuals sharing this concern.
Biden: White supremacists ‘most unsafe people’ in America
With his impeachment trial concluded, Mr Trump's reappearance on cable news suggests he may be preparing to resume his public profile.
As of Thursday evening, federal data showed there have been 858,217 COVID-19 cases in Canada, including 21,865 deaths, since the beginning of the pandemic.
"We are not out of the woods yet", said Adam MacNeil of the Centers for Disease Control and Prevention.
Canada has secured access to 20 million doses of the AstraZeneca vaccine.
While it may prove surmountable in the end, health policymakers will still have to grapple with the question of which vaccines to deploy, and in what order, ahead of potential repeat inoculations. This panel makes recommendations on how to use vaccines. "We are very, very confident in our ability to meet targets", says Alcorn.
In Washington state, health officials see some clear need for one-and-done vaccinations, including sailors in the maritime industry, who can spend months on cargo and fishing vessels.
"I think the key numbers that are important is that if you look across all the clinical trials at the tens of thousands of people that were involved, the number of cases of people that died from COVID-19, that got vaccines, was zero", Sharma said.
Other parts of the world already are facing which-is-best challenges. They also endorsed the vaccine for emergency use authorization. But the review noted that the vaccine had lower efficacy among higher-risk older adults in the trial, a finding that experts hope will not discourage some people from taking it.
In the USA, health officials say it's critical for the government to send a clear message. But he, too, urged people to get whichever vaccine is available to them.